What is ThinkGenetic?
Founded in 2015 and headquartered in Virginia, ThinkGenetic operates at the forefront of precision medicine. The company utilizes proprietary artificial intelligence solutions to identify individuals suffering from both diagnosed and undiagnosed genetic conditions. By streamlining the diagnostic journey, ThinkGenetic addresses a significant inefficiency in the healthcare market, where patients often face years of uncertainty. Their platform serves as a vital bridge for clinicians and patients alike, transforming complex genomic data into actionable clinical pathways. This market position is bolstered by a commitment to data-driven patient advocacy and the integration of machine learning into standard diagnostic workflows.
How much funding has ThinkGenetic raised?
ThinkGenetic has raised a total of $2M across 2 funding rounds:
Other Financing Round
$1.5M
Other Financing Round
$500K
Other Financing Round (2019): $1.5M, investors not publicly disclosed
Other Financing Round (2021): $500K led by Ochsner Lafayette General Healthcare Innovation Fund
Key Investors in ThinkGenetic
Ochsner Lafayette General Healthcare Innovation Fund
A specialized investment vehicle focused on accelerating the adoption of transformative technologies within the clinical healthcare environment.
Undisclosed Institutional Partner
Undisclosed investor participating in the funding round.
Undisclosed Strategic Backer
Undisclosed investor participating in the funding round.
What's next for ThinkGenetic?
With the infusion of this recent capital, ThinkGenetic is well-positioned to scale its diagnostic infrastructure and expand its reach within the enterprise healthcare sector. The company is expected to prioritize the refinement of its AI algorithms to improve diagnostic accuracy and reduce the time-to-diagnosis for rare disease patients. Furthermore, the strategic focus will likely shift toward deepening partnerships with major healthcare systems and research institutions. As the firm moves into this next phase of growth, the emphasis will remain on enhancing the scalability of its software-as-a-service model, ensuring that its diagnostic tools are seamlessly integrated into the broader clinical landscape to drive better patient outcomes and operational efficiencies.
See full ThinkGenetic company page
